Bristol-Myers Tops Profit Estimates on Tax Benefit

Bristol-Myers Squibb Co.’s fourth-quarter earnings beat analysts’ estimates after the company took a tax benefit from a hepatitis C drug that failed last year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.